Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity
Related Experiment Video
Updated: Jan 21, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Pei-Lu Song1, Gang Wang2, Yuan Su1
1Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Abstract:
p21 activated kinase 4 (PAK4), which belongs to the serine/threonine (Ser/Thr) protein kinase family, is a representative member of the PAK family and plays a significant role in multiple processes associated with cancer development. In this study, structure-based virtual screening was performed to discover novel and selective small molecule scaffolds, and a 6-hydroxy-2-mercapto-3-phenylpyrimidin-4(3H)-one-based compound (SPU-106, 14#) was identified as an effective PAK4 inhibitor. By combining both a molecular docking study and molecular dynamics (MD) simulation strategies, the binding mode was determined in the PAK4 site. The SPU-106 compound could efficiently and selectively bind to the PAK4 kinase domain at an IC50 of 21.36 μM according to the kinase analysis. The designed molecular probe demonstrated that SPU-106 binds to the kinase domain in the C-terminus of PAK4. Further investigation revealed that the SPU-106 had a strong inhibitory effect on the invasion of SGC7901 cells but without any cytotoxicity. The western blot analysis indicated that the compound potently inhibited the PAK4/LIMK1/cofilin and PAK4/SCG10 signaling pathways. Thus, our work shows the successful application of computational strategies for the discovery of selective hits, and SPU-106 may be an effective PAK4 inhibitor for further development as an antitumor agent.
Insights
Researchers discovered SPU-106, a novel small molecule inhibitor targeting p21 activated kinase 4 (PAK4). This compound effectively inhibits cancer cell invasion by blocking key signaling pathways without causing cytotoxicity, offering potential as an antitumor agent.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- p21 activated kinase 4 (PAK4) is a serine/threonine protein kinase implicated in cancer development.
- Targeting PAK4 is a promising strategy for cancer therapy.
Purpose of the Study:
- To discover novel and selective small molecule inhibitors of PAK4 using structure-based virtual screening.
- To characterize the binding mode and inhibitory potential of the identified compound.
Main Methods:
- Structure-based virtual screening and molecular docking.
- Molecular dynamics (MD) simulations.
- Kinase activity assays and western blot analysis to assess pathway inhibition.
Main Results:
- A novel compound, SPU-106, was identified as an effective and selective PAK4 inhibitor.
- SPU-106 binds to the PAK4 kinase domain with an IC50 of 21.36 μM.
- SPU-106 inhibited SGC7901 cell invasion without cytotoxicity and suppressed PAK4/LIMK1/cofilin and PAK4/SCG10 signaling.
Conclusions:
- Computational strategies successfully identified a selective PAK4 inhibitor.
- SPU-106 demonstrates potential as an antitumor agent for further preclinical development.
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Reliability and Validity
Titrimetric Methods: Types and Commonly Used Strategies
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Discovery: Overview

